G.J. Ossenkoppele
YOU?
Author Swipe
View article: Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial Open
View article: Table of Contents
Table of Contents Open
View article: ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0 Open
View article: Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine Open
Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, an…
View article: Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome Open
View article: Evaluating ivosidenib for the treatment of acute myeloid leukemia
Evaluating ivosidenib for the treatment of acute myeloid leukemia Open
Ivosidenib is a promising, most probably practice changing, new drug for the treatment of IDH1-mutated AML. Current phase III trials are ongoing to evaluate the addition of ivosidenib to the current standards-of-care. In the near future, m…
View article: Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS Open
View article: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS Open
View article: PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC‐PRIVATE DATA COLLECTION LEADS THE WAY ‐ FIRST RESULTS OF THE “PROOF‐OF‐PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA
PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC‐PRIVATE DATA COLLECTION LEADS THE WAY ‐ FIRST RESULTS OF THE “PROOF‐OF‐PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA Open
Background: The HARMONY Alliance is the the largest Innovative Medicines Initiative (IMI) European public‐private partnership that aims to improve outcomes of patients with hematological malignancies (HMs) by establishing consensus outcome…
View article: Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia Open
Background Disease recurrence remains the major cause of death in adults with acute myeloid leukaemia (AML) treated using either intensive chemotherapy (IC) or allogenic stem cell transplantation (allo‐SCT). Aims The timely delivery of mai…
View article: In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL Open
View article: Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry Open
View article: Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio Open
View article: Issue Information ‐ TOC1
Issue Information ‐ TOC1 Open
View article: Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia Open
Acute myeloid leukemia is a clonal neoplasm derived from myeloid progenitor cells with a varying outcome. The initial goal of treatment is the achievement of complete remission, defined for over 40 years by morphology. However, without add…
View article: Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study Open
The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep molecular response (MR(4) (BCR…
View article: Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG Open
Despite incremental progress over the last several decades, adult acute myeloid leukemia (AML) remains difficult to treat, and many patients experience therapeutic resistance, i.e. never attain a complete remission (CR) despite living long…
View article: Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study
Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study Open